Recommended dosing1*
EVERY OTHER WEEK (EOW) DOSING STARTING AT WEEK 0, IN COMBINATION WITH
METHOTREXATE (MTX)
Pediatric UV patients weighing <30 kg
Pediatric UV patients weighing ≥30 kg
In pediatric UV, there is no experience in the treatment with HUMIRA without concomitant treatment with MTX.1
When HUMIRA is initiated in patients 6 years of age or older, an optional loading dose of 40 mg for patients <30 kg or 80 mg for patients
≥30 kg may be administered one week prior to the start of maintenance therapy.1
No clinical data are available on the use of a loading dose for HUMIRA in children less than 6 years of age.1
For patients who need to administer the 20 mg dose, 20 mg pre-filled syringes are available for pediatric use.1
40 mg Pens and 40 mg pre-filled syringes are available for patients who need to administer the 40 mg dose.1
There are no data in the use of HUMIRA in children aged less than 2 years for this indication.1
Please see the Product Monograph for complete dosing and administration instructions.
EOW=every other week
* Patients may self-inject HUMIRA if their physician determines that it is appropriate and with medical follow-up, as necessary, after proper training in
subcutaenous injection technique.
Safety information
Click here for additional information and for a link to the Product Monograph discussing:
• Contraindications in patients with severe infections such as sepsis, tuberculosis (TB) and opportunistic infections, and moderate to severe heart failure (NYHA class III/IV).
• The most serious warnings and precautions regarding hepatosplenic T-cell lymphoma (HSTCL), serious infections and pediatric malignancy.
• Other relevant warnings and precautions regarding concurrent administration with other biologic disease-modifying antirheumatic drugs (DMARDs) or other tumour necrosis factor (TNF) antagonists not recommended, switching between biological DMARDs, surgery, patients with congestive heart failure, hematologic events, hypersensitivity reactions, autoimmunity, immunosuppression, immunizations, infections including TB, opportunistic infections and hepatitis B virus reactivation, malignancies including malignancies in pediatric patients and young adults, lymphoma and non-lymphoma malignancy, neurologic events, uveitis and central demyelinating disorders, pregnant or nursing women, and geriatrics.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
The Product Monograph is also available by calling us at 1-866-8HUMIRA (1-866-848-6472).
Reference:
1. HUMIRA Product Monograph. AbbVie Corporation.
CA-HUMR-220011A / OC23